INTERFERON-?? TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1
Authors:
- Brent L. WoodBWBrent L. Wood
- Daniel E. SabathDSDaniel E. Sabath
- Jackline S. JosephJJJackline S. Joseph
- Catherine Stehman-BreenCSCatherine Stehman-Breen
- Virginia C. BroudyVBVirginia C. Broudy
- 1 December 1998
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (12) , 1770-1779
Abstract
Posttransplant lymphoproliferative disorder (PTLD) has been treated with decreased immunosuppression, antiviral medications, anti-B lymphocyte agents, radiation therapy, and/or chemotherapy. However, a standardized stepwise approach to treatment has not been previously evaluated. In the present study, 19 consecutive patients presenting to a single institution with newly diagnosed PTLD were treated according to a sequential protocol that consisted of (1) a reduction in immunosuppressive medications plus, if feasible, resection or definitive radiation therapy of localized disease, (2) interferon-α, and (3) systemic chemotherapy. Of the 3 patients presenting exclusively with localized disease, two were treated with resection of pulmonary parenchymal nodules and one was treated with radiation therapy to a paraspinous mass, without evidence of recurrence at a mean follow-up of 31 months (range, 8 to 46 months). Sixteen patients presented with PTLD not amenable to local therapy, and they were treated daily with 3×106 units/m2 subcutaneous interferon-α. Total regression of PTLD (defined as disappearance of the tumor mass by physical examination or computed tomography scanning) was found in 8 of 14 patients who received at least 3 weeks of interferon therapy. Interferon-α therapy was continued for 6 to 9 months in the eight patients judged to be responders. None of these patients have relapsed to date with the same neoplastic clone. Two patients, however, developed new neoplastic clones. Seven patients received systemic chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (n=1), EPOCH (etoposide, vincristine, and doxorubicin administered as a continuous infusion, with an intravenous bolus of cyclophosphamide and oral prednisone) (n=4), or EPOCH followed by DHAP (dexamethasone, cytarabine, and cisplatin) (n=2) after failure of interferon-α; five patients had a complete response. Only 1 of the 19 patients died of uncontrolled PTLD. These results suggest that the majority of solid organ transplant recipients who develop PTLD can be safely and successfully treated using a sequential approach to therapy.Keywords
This publication has 71 references indexed in Scilit:
- Minimal change glomerulonephritis with reversible proteinuria during interferon α2a therapy for chronic myeloid leukemiaAmerican Journal of Hematology, 1995
- Interferon-induced acute renal failure: a case report and literature reviewMedical Oncology, 1995
- Treatment of large granular lymphocyte leukemia with oral low-dose methotrexateBlood, 1994
- Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipientsBlood, 1994
- Clinical characteristics of post-transplant lymphoproliferative disordersThe American Journal of Medicine, 1994
- Lymphoproliferative disorder early after cardiac transplantationThe American Journal of Cardiology, 1991
- Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases of after solid organ transplantationThe American Journal of Medicine, 1989
- Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infectionJournal of Clinical Immunology, 1989
- Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantationBlood, 1988
- Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic resultsThe American Journal of Medicine, 1986